-
Treatment Area:
Parkinson's Disease
-
Study Aim:
To advance our understanding of Parkinson’s Disease and accelerate the development of advanced therapies to improve outcomes for patients.
-
Recruitment Target:
Ongoing patient recruitment of patient's diagnosed with Parkinson's Disease.
-
Treatment Area:
Multiple Sclerosis
-
Study Aim:
To discover whether the genes that contribute to MS risk are the same or different for people of non-European ancestry, with a focus on people from African & South Asian backgrounds.
-
Recruitment Target:
400 patients
-
Treatment Area:
Respiratory Syncytial Virus (RSV)
-
Trial Site Locations:
Fylde Coast Clinical Research Blackpool, Royal Devon University Healthcare NHS Foundation Trust, Royal Free Hospital London
-
Study Aim:
To evaluate the safety and immune response of an investigational vaccine (mRNA-1345) aimed at preventing RSV infection in high risk adults
-
Recruitment Target:
100 patients
-
Treatment Area:
Parkinson's Disease
-
Trial Site Locations:
Newcastle University, Campus for Ageing and Vitality.
-
Study Aim:
This study, run by The Michael J. Fox Foundation for Parkinson’s Research, is exploring the link between loss of smell and brain disease by providing study participants with a simple scratch-and-sniff test.
-
Recruitment Target:
15,000 patients without Parkinson's Disease.
-
Treatment Area:
Alopecia Areata
-
Trial Site Locations:
Queen Anne Street Medical Centre, London
-
Study Aim:
To assess the safety, efficacy & dose response characterisation of STSO1 (Dithranol/ProSilic) administered topically, once daily, to affected scalp areas for 6 months, in patients who have mild to moderate Alopecia Areata.
-
Recruitment Target:
100 patients with mild to moderate Alopecia
-
Treatment Area:
Chronic Kidney Disease and Pruritus
-
Trial Site Locations:
The Royal London Hospital, Hull University Teaching Hospital, Newcastle Hospitals NHS Foundation Trust, Nottingham University Teaching Hospital, Churchill Hospital, Oxford University
-
Study Aim:
To evaluate the efficacy and safety of MC2-25 Cream and MC2-25 vehicle in subjects with chronic kidney disease-associated pruritus (CKD aP)
-
Recruitment Target:
22 Patients: Non-Dialysis CKD stage 3
22 Patients: Non-dialysis CKD stage 4/5
Total: 44 Patients
-
Treatment Area:
Asthma
-
Trial Site Locations:
Queen Anne Street Medical Centre London, Egin Research High Wycombe, Royal Liverpool University Hospital
-
Study Aim:
To understand the safety and efficacy of the drug AZD1402 in adults with moderate asthma, who regularly use inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs)
-
Recruitment Target:
30 patients